Australia markets close in 4 hours 23 minutes
  • ALL ORDS

    7,759.90
    +69.70 (+0.91%)
     
  • ASX 200

    7,444.60
    +69.70 (+0.95%)
     
  • AUD/USD

    0.7473
    -0.0004 (-0.05%)
     
  • OIL

    83.00
    +0.04 (+0.05%)
     
  • GOLD

    1,767.30
    -3.20 (-0.18%)
     
  • BTC-AUD

    85,802.48
    +2,254.39 (+2.70%)
     
  • CMC Crypto 200

    1,485.18
    +21.83 (+1.49%)
     
  • AUD/EUR

    0.6421
    +0.0001 (+0.02%)
     
  • AUD/NZD

    1.0440
    -0.0007 (-0.07%)
     
  • NZX 50

    13,134.08
    +68.16 (+0.52%)
     
  • NASDAQ

    15,410.72
    +109.83 (+0.72%)
     
  • FTSE

    7,217.53
    +13.70 (+0.19%)
     
  • Dow Jones

    35,457.31
    +198.70 (+0.56%)
     
  • DAX

    15,515.83
    +41.36 (+0.27%)
     
  • Hang Seng

    25,787.21
    +377.46 (+1.49%)
     
  • NIKKEI 225

    29,412.18
    +196.66 (+0.67%)
     

Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., September 22, 2021--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29th, 2021 at 11:20 a.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit https://scholarrock.com/ or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005707/en/

Contacts

Scholar Rock:
Investors/Media
Catherine Hu
chu@scholarrock.com

Media:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
917-565-2204

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting